Welcome to our dedicated page for Omnicell Com news (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell Com stock.
Omnicell, Inc. (NASDAQ: OMCL) develops healthcare technology for autonomous medication management across pharmacy and nursing care settings. Its updates cover financial results, product bookings, recurring revenue, connected-device demand, and product launches such as Omnicell Titan XT and the OmniSphere platform.
Company news also includes healthcare conference presentations, customer engagement programs, clinical leadership roles, and innovation updates tied to automation, AI-enabled intelligence, software workflows, data analytics, and expert services for medication management in healthcare facilities.
Omnicell (Nasdaq:OMCL) will present at the BofA Securities 2026 Healthcare Conference on Tuesday, May 12, 2026 at 8:40 a.m. PDT. Live and archived webcasts will be available on Omnicell's investor website for access by investors and analysts.
Omnicell (NASDAQ:OMCL) appointed Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer, a newly created role aimed at bringing health system pharmacy leadership perspective to Omnicell’s innovation roadmap and portfolio decisions. Couldry has 30 years of hospital pharmacy leadership experience and joins from The University of Kansas Health System.
His responsibilities include informing clinical guidance, shaping thought leadership, and aligning solutions to clinical and operational needs across complex care environments.
Omnicell (NASDAQ:OMCL) reported Q1 2026 results with total revenues of $310 million, up 15% year-over-year, GAAP net income of $11 million ($0.25 diluted EPS) and non-GAAP net income of $25 million ($0.55 diluted EPS). Non-GAAP EBITDA was $45 million. Cash and equivalents totaled $239 million, with $350 million available on the revolving credit facility. The company raised full-year 2026 non-GAAP EBITDA guidance to $153M–$168M and non-GAAP EPS to $1.80–$2.00. Customer engagement began for Omnicell Titan XT and OmniSphere.
Omnicell (Nasdaq: OMCL) will release its first quarter 2026 financial results before market open on Tuesday, April 28, 2026.
The company will host a conference call and webcast the same day at 8:30 a.m. ET; dial-in numbers and Conference ID 9381205 are provided, and a live/archived webcast will be posted on the Investor Relations website.
Omnicell (NASDAQ:OMCL) reported fiscal year and fourth quarter 2025 results on February 5, 2026, with FY2025 total revenue $1.185B (up 7% YoY) and Q4 revenue $314M (up 2% YoY). The company launched the new Titan XT automated dispensing system and reported ARR $635.6M.
GAAP net loss for Q4 2025 was $2M (loss of $0.05 per diluted share); FY2025 GAAP net income was $2M ($0.04 per diluted share). FY non-GAAP net income was $75M ($1.62 per diluted share). 2026 guidance includes total revenue $1.215B–$1.255B and ARR $680M–$700M.
Omnicell (Nasdaq:OMCL) will release fourth quarter and full year 2025 financial results before market open on Thursday, February 5, 2026. Management will host a conference call and webcast to discuss results at 8:30 a.m. ET the same day.
Investors can join by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (international) using Conference ID 4203777. A live and archived webcast will be available on Omnicell's Investor Relations events page at https://ir.omnicell.com/events-and-presentations/.
Omnicell (NASDAQ:OMCL) launched Titan XT, an enterprise automated dispensing system powered by OmniSphere, the company’s cloud-based, HITRUST-certified medication management platform. Titan XT extends OmniSphere to nursing care areas, aiming to unify inventory, enable a global formulary, and support perpetual inventory across large health systems.
Key operational points: a customer reported ~70% time savings for cabinet restocking; Titan XT is available for purchase in the United States now; international availability is anticipated later in 2026, and ongoing OmniSphere releases begin in early 2027.
Omnicell (Nasdaq: OMCL) will host an Innovation Update and an investor Q&A session at the ASHP Midyear Clinical Meeting & Exhibition in Las Vegas on Monday, December 8, 2025.
The Innovation Update is in person only at Booth #1241 at 3:00 PM PT. The Q&A session is in person and will be webcast at 4:00 PM PT, with a live and archived webcast available on Omnicell's investor website.
Omnicell (Nasdaq: OMCL) will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 1:00 p.m. ET.
Live and archived webcasts of the presentation will be available via the company’s investor relations site at https://ir.omnicell.com/events-and-presentations/.
Omnicell (Nasdaq: OMCL) announced that its Specialty Pharmacy Services business earned URAC Health Care Management Certification, effective Oct 1, 2025 through Oct 1, 2028. The certification recognizes enterprise-grade clinical oversight, operational governance, and specialty pharmacy support under URAC's rigorous standards for clinical governance, risk management, and performance improvement.
Omnicell says the URAC-certified service model enables health systems to launch and scale in-house specialty pharmacy and 340B programs under their own licenses while retaining brand, clinical, and financial ownership.